Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Tumor Progression02:07

Tumor Progression

7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
Tumor Progression02:07

Tumor Progression

3.5K
3.5K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Neural Regulation01:37

Neural Regulation

44.7K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Study protocol: double-blind, randomized, prospective, placebo controlled parallel group phase II study to investigate the effect of glycerol phenylbutyrate (GPB) on neurofilament light chain (NfL) levels in patients with corticobasal syndrome (CBS).

Neurological research and practice·2026
Same author

From clinical phenotypes to molecular stratification: early differential diagnosis of four-repeat tauopathies.

Frontiers in aging neuroscience·2026
Same author

Measuring the Prodrome Promise and Challenges of the Prodromal Synucleinopathy Rating Scale.

Neurology·2026
Same author

Planimetric and Linear MRI Markers for Progressive Supranuclear Palsy Classification: A Large Multicohort International Study.

Radiology·2026
Same author

Feasibility of short imaging protocols for [<sup>18</sup>F]fluordeprenyl-D2 PET in autoimmune encephalitis and multiple system atrophy.

European journal of nuclear medicine and molecular imaging·2026
Same author

Biologic Definition of Parkinson Disease: A Pivotal Role for Molecular Imaging.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Related Experiment Video

Updated: Mar 28, 2026

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

21.1K

Progressive supranuclear palsy: progression and survival.

Julieta E Arena1, Stephen D Weigand2, Jennifer L Whitwell3

  • 1Department of Neurology, Mayo Clinic, 200 First street SW, Rochester, MN, 55905, USA.

Journal of Neurology
|December 26, 2015
PubMed
Summary
This summary is machine-generated.

This study tracked clinical milestones in progressive supranuclear palsy (PSP). Sleep disturbances and hallucinations were linked to a higher risk of death in PSP patients.

Keywords:
DiagnosisProgressive supranuclear palsySurvivalSymptoms

More Related Videos

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases
09:36

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Published on: June 28, 2019

10.8K
Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo
09:44

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Published on: June 2, 2019

23.0K

Related Experiment Videos

Last Updated: Mar 28, 2026

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

21.1K
Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases
09:36

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Published on: June 28, 2019

10.8K
Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo
09:44

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Published on: June 2, 2019

23.0K

Area of Science:

  • Neurology
  • Neurodegenerative Diseases
  • Clinical Research

Background:

  • Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease with poorly understood clinical progression and survival correlations.
  • Previous descriptions of PSP's natural history lack detailed timelines for symptom onset and their impact on survival.

Purpose of the Study:

  • To determine the prevalence of various symptoms at different stages of PSP.
  • To estimate the time of appearance for characteristic PSP clinical symptoms.
  • To investigate the association between specific clinical symptoms and patient survival.

Main Methods:

  • Prospective study of 35 PSP patients over 2 years with 6-month assessments.
  • Data collection focused on symptom prevalence and timing of onset.
  • Statistical analysis to correlate clinical symptoms with survival outcomes.

Main Results:

  • Motor symptoms were universal (100%) at baseline, followed by cognitive/behavioral (89%) and bulbar/systemic (80%).
  • Early symptoms included slowness, falls, neck stiffness, and gaze difficulties; gait/balance issues worsened over time.
  • Sleep disturbances (60% prevalence) and potential hallucinations correlated with increased mortality risk.

Conclusions:

  • Understanding PSP symptom progression and milestones aids in earlier diagnosis and prognostic accuracy.
  • Identifying specific symptoms like sleep disturbances can help predict survival outcomes in PSP.
  • This research enhances the clinical knowledge base for managing progressive supranuclear palsy.